newsfilter
← Latest News
PR Newswire·

Elevation Oncology Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress

On track to report additional interim seribantumab data from the Phase 2 CRESTONE study in the first half of 2023Preparations are underway to initiate a Phase 1 clinical trial of EO-3021 in the US in 2023NEW YORK, Nov.